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Background  & aims:  This  study  examined  the effects  of a  traditional  Chinese  medicine  decoction,  Kuan-
Sin-Yin  (KSY),  on  patients  with  chronic  hepatitis  C (CHC)  in  a randomised  and  placebo-controlled  clinical
trial.
Methods:  This  trial enrolled  70 subjects  with  CHC  who  were  randomised  into  2 groups  each  with  35 partic-
ipants.  In total,  29 participants  in  the  therapeutic  group  took  100  mL of the herbal  decoction  daily,  whereas
28  in  the  control  group  took  an  herbal  placebo  with  the  same  dose  and  frequency  for  the  6-week  study.  The
primary  outcomes  were  liver  function  and  viral  load.  Secondary  measurements  included  haematopoietic
and  biochemical  proﬁles,  safety  parameters,  and a  quality  of life  survey.  All  measurements  were  collected
at the  beginning  of the study  and after  6 weeks.
Results: In within-group  analysis,  signiﬁcant  decreases  of glutamate  pyruvate  transaminase  (GPT)
31.7  ±  75.2  IU/L  and  glutamate  oxaloacetate  transaminase  (GOT)  20.3  ±  45.7 IU/L  were  found  in the  KSY
group  (p =  0.031  and 0.024,  respectively).  In  the  between-group  analysis,  KSY  reduced  serum  GOT  and  GPT
levels  by  more  than  20 IU/L (p = 0.027  and  0.047,  respectively).  KSY  also  signiﬁcantly  decreased  viral  load
by 0.3  log  units  (p  =  0.047).  In addition,  KSY  signiﬁcantly  decreased  serum  triglyceride  16.9 ± 27.5 mg/dL
(p  = 0.024).
Conclusions:  This  study  demonstrates  that taking  the  KSY  herbal  decoction  for 6  weeks  improves  liver
function  and serum  triglyceride  levels  and  is safe  for patients  with  CHC.  The  potential  long-term  effects
of  KSY  on  lipid metabolism  related  hepatoprotection  and  viral  clearance  warrant  further  investigation.
© 2016  The  Author(s).  Published  by  Elsevier  Ltd. This  is an open  access  article  under  the  CC  BY-NC-ND
Abbreviations: KSY, Kuan-Sin-Yin; CHC, chronic hepatitis C; HCV, hepatitis C
irus; CAM, complementary and alternative medicine; TCM, traditional Chinese
edicine; NHIRD, national Health Insurance database; anti-HCV Ab, anti-hepatitis C
irus antibody; ITS, internal transcribed space; HPLC, high-performance liquid chro-
atography; GOT, glutamate oxaloacetate transaminase; GPT, glutamate pyruvate
ransaminase; AFP, alpha-fetoprotein; QOL, quality of life; XCHT, Xiao Chai Hu Tang.
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1. Introduction
Infection with hepatitis C virus (HCV) affects an estimated 180
million people globally. HCV is a leading cause of chronic hepati-
tis, cirrhosis, and liver cancer and a primary indication for liver
transplantation in the western world.1 Taiwan is an endemic area
of hepatitis C, and the seroprevalence of positive anti-HCV infec-
tion among adults in Taiwan has been reported to be 2.7%–8.6%
depending on the geographic region.2
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There is no medication that can completely eradicate the virus so
ar, despite the increased and sustained viral response to new pro-
ease inhibitors. The currently recommended therapy for chronic
CV infection is a combination of weekly pegylated interferon
lpha and daily Ribavirin. Genotype is clinically important in deter-
ining potential response to interferon based therapy and the
equired duration of such therapy. HCV genotypes 1 and 4 are
ess responsive to interferon-based treatment than are the other
enotypes.3, 4 Several antiviral drugs have been approved for hep-
titis C, but they induce signiﬁcant dose-dependent side effects
nd drug resistance.5, 6 Moreover, the combined therapy of direct-
cting antivirals with current treatments is quite expensive and
ill likely not be accessible to all patients worldwide.7 Thus, many
atients with chronic hepatitis C (CHC) seek complementary and
lternative medicine (CAM) to improve their liver function and con-
rol the progression of CHC.8–10 CAM such as silymarin has been
hown to be potentially beneﬁcial and safe treatment option for
HC in some clinical surveys.11, 12
Traditional Chinese medicine (TCM) is a well-established CAM
f the health care system in Taiwan. More than 60% of outpatients
n the National Health Insurance database (NHIRD) had used TCM
rom 1996 to 2001.13 TCM is widely used in the Chinese-speaking
reas of China, Hong Kong, and Singapore.14, 15 TCM also has been
sed in some clinical trials on chronic hepatitis B 16 and combina-
ion with interferon based therapy for CHC.17
In TCM theory, abnormal liver function of patients with CHC
ight be caused by impairment of qi ﬂow in the human body. The
uthors designed a potential TCM decoction, Kuan-Sin-Yin (KSY),
hich supported qi and regulated the qi ﬂow of CHC patients. KSY
as been used to improve liver function and quality of life in hep-
Assess ed for eli 
Analysed (n=29)
6 sub jec ts (17 %) discontinued
4 withdrew voluntarily
2 did not attend follow-up
Allocated to and received KSY (n=35) 
Randomi ze
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atitis B virus carriers in clinical trial.18 Kuan-Sin-Yin (KSY) also has
been clinically used to treat patients with colon cancer to improve
their quality of life and cancer-related fatigue.19 In view of these
reports, we conducted a randomised and placebo-controlled clin-
ical trial to evaluate the effects of KSY on liver function and viral
load in patients with CHC.
2. Methods
2.1. Study design and participants
This study was a randomised and placebo-controlled trial con-
ducted from August 2012 to March 2014 at Taipei City Hospital
in Taiwan. Among the 85 registered patients with CHC  screened
at our outpatient clinic, 70 met  the following criteria and were
enrolled: (1) anti-hepatitis C virus antibody (anti-HCV Ab) positive,
(2) aged between 18 and 65 years old, (3) 40 IU/L < GPT < 200 IU/L,
(4) not taking any antiviral agents either currently or for the last 3
months, and (5) understands the purpose and process of the study
and signed the informed consent. The exclusion criteria included
(1) consumption of more than 20 g of alcohol/day; (2) presence of
other forms of liver disease, including any other viral hepatitis, iron
storage disease, Wilson’s disease, alpha 1 antitrypsin deﬁciency,
autoimmune chronic active hepatitis, primary biliary cirrhosis and
sclerosing cholangitis; (3) currently undergoing any other antivi-
ral therapy, including interferon, ribavirin, or herbal therapies;
(4) total bilirubin greater than 2.0 mg/dL; (5) major complications
within 6 months, including myocardial infarction, stroke, severe
trauma; (6) pregnant or breast-feeding women; (7) psychiatric
history; (8) human immunodeﬁciency virus (HIV) infection; and
gibility (n= 85 )
Excluded (n=15)
Did not meet inclusion criteria (n=12 )
Declined to participate (n=3)
7 sub jects (20 %) discontinued
5 withdrew voluntarily
2 did not attend follow-up
Allocated to and received placebo (n=35 ) 
Analysed (n= 28)
d (n=70)
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8) any other conditions not suitable for trial as evaluated by the
hysician.
Informed consent was obtained from each enrolled participant.
etters explaining the purpose of the study were sent to all the
atients inviting them to participate. A signed informed consent
as obtained from each of the 70 subjects enrolled in the study,
nd they were randomly allocated to receive the KSY, as the exper-
mental group, or a 16-fold dilution of the KSY, as the control group
Fig. 1). A 16-fold dilution of KSY is the equivalent to a placebo
ccording to our previous work.18
According to the 1:1 random sequence generated by computer
oftware program, both KSY and placebo decoctions were con-
ained in the same packs, which were administered by a blinded
esearch assistant. During this study, health care giver and data
ollector were blinded to group assignment. Both groups received
heir respective treatment for 6 weeks. During the 6-week study
eriod, all participants were asked to maintain their regular diet
nd lifestyle. Every two weeks, subjects returned to our clinics and
eported to the study center for adverse events and compliance
ssessment. Subjects were free to withdraw at any time. 6 subjects
n KSY group and 7 subjects in placebo group discontinued in this
tudy. Among the discontinued KSY subjects, 4 of them were male,
nd 4 of them withdrew voluntarily without adverse events. Among
he discontinued placebo subjects, 4 of them were male, and 5 of
hem withdrew voluntarily without adverse events.
The study protocol conforms to the ethical guidelines of the
975 Declaration of Helsinki and was approval by the Human Ethics
ommittee of Taipei City Hospital. This trial (NCT01708733) was
egistered with the ClinicalTrials.gov Registry on 15 October 2012
nd complied with the CONSORT 2010 statements. The support-
ng CONSORT checklist is available as supporting information (see
upplementary material).
.2. Sample preparation and treatment
The KSY decoction contained 7 Chinese herbs (Table 1), which
ere evaluated by contamination screening for heavy metals, pes-icides and microbial limits. All of the herbs were prepared in the
harmacy Department, Branch of Linsen and Chinese Medicine,
aipei City Hospital in Taiwan. For the experimental group, the
SY herbs were soaked in water at a ratio of 1:3 (g:mL), boiled
able 1
he components and mechanisms of herbal medicine in KSY.
Chinese name Pharmaceutical name 
Dan Shen Dried root of Codonopsis pilosula
(Franch.) Nannf.
Bai Zhu Rhizome of Atractylodes macrocephalan
Koidz.
Fu Ling Dried sclerotium of the fungus, Poria
cocos (Schw.) Wolf.
Huang Qi Dried root of Astragalus membranaceus
(Fisch.) Bunge
Huo Xiang Dried branches and leaves of Agastache
rugosa (Fisch.et Mey.) O. Ktze.
Nu Zhen Zi Dried fruit of Ligustrum lucidum Ait. 
Gan Cao Dried root and rhizome of Glycyrrhiza
uralensis Fisch.
 net weight of 36 g of herbal medicine was extracted with 100 mL water in each pack. Ks in Medicine 27 (2016) 114–122
at 1.5 atmospheres and 120 ◦C for 4 h in an automatic Chinese herb
boiling machine, and separated into 100 mL  packs with an auto-
matic Chinese herb packing machine. For the control group, the
KSY herbs, prepared as described above, were diluted 16-fold to a
non-curative dose. The KSY decoction was stored at 4 ◦C until the
experiment. Participants were instructed to take one pack of the
decoction 30 min  after breakfast each day for 6 weeks.
To conﬁrm the quality of the KSY, two  tests were performed:
internal transcribed space (ITS) sequencing of seven crude herbs
that are ingredients of KSY and high-performance liquid chro-
matography (HPLC) of the ﬁnal product of the KSY decoction.
ITS technology can be used as a basis for interpretation.20 We
compared these sequences with the NCBI nucleotide database to
verify their botanic origins. All seven herbal ingredients of KSY
exhibited correct botanic origins and similar ITS sequences except
several SNP sites that were more comparable with different ref-
erence sequences in the database. This test was replicated several
times, and the conﬁrmed sequences of the seven crude herbs are
listed in Table 2.
2.3. HPLC ﬁngerprint analysis of KSY decoction
To prepare the KSY, concentrated aqueous extracts of seven Chi-
nese herbs were mixed in 100 mL  of sterile water in ﬁxed ratios:
3 g each of Codonopsis pilosula (Franch.) Nannf.,  Poria cocos (Schw.)
Wolf., Atractylodes macrocephalan(Koidz.),  Astragalus membranaceus
(Fisch.), and Agastache rugosa (Fisch.et Mey.) O. Ktze., and 1.5 g each
of Glycyrrhiza uralensis Fisch. and Ligustrum lucidum Ait. This stan-
dard formula was boiled for 30 min  and then centrifuged at 2000g
for 5 min  at room temperature. The supernatant was collected and
dried into a powder with a freeze dryer (SP Scientiﬁc #FM25EL-
85), and 0.2 g of the powder was suspended in 70% methanol and
ﬁltered through a 0.2 m HPLC membrane. The HPLC machine
(Hitachi-L7100) was set with the following parameters: column,
LichroCART 250-4 Cat. 1.50252 RP-18e (5 M);  gradient range,
10–90% methanol; ﬂow time, 120 min; detector, 254 nm; ﬂow rate,
1 mL/min; injection volume, 20 L; and internal control, evodi-
amine. The herbal decoction ingredients of KSY, as detected by
HPLC, are shown in Fig. 2.
Ratio Possible hepatoprotective/antiviral mechanism
2 Suppresses excessive regulatory T cells via TLR4 signalling
and triggers a shift of TH2 to TH1 via the activation of CD4T
cells in sepsis29
2 Exerts protective and therapeutic effects against hepatic
ischemia reperfusion injury in rats, which is associated
with its antioxidant properties and inhibition of NF-kB
activation35
2 Activates primary macrophage via TLR4 and Th1 immune
responses and supports Th2 cytokine and IgE production22
2 Enhance the immune responses of HBV DNA vaccine by
promoting dendritic cell maturation and inhibiting the
production of regulatory T cells23
2 Protects against d-galactosamine and lipopolysaccharide –
induced liver injury by suppressing TLR4 signalling and
enhancing autophagic ﬂux26
1 Fructus Ligustri Lucidi (FLL) directly inhibits HCV NS5 B
RNA-dependent RNA polymerase activity. Oleanolic acid
and ursolic acid are two antiviral components in FLL
aqueous extracts that signiﬁcantly suppress the replication
of HCV genotype 1b and HCV genotype 2a JFH1 virus32
1 Dose-dependently suppressed HCV replication30
SY: Kuan-Sin-Yin decoction.
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Table  2
ITS sequences of seven crude herbs in KSY.
Crude herb ITS sequence
Codonopsis pilosula
(Franch.) Nannf.
GCGAAATGCGATACTTGGTGTGAATTGCAGAATCCCGTGAACCATCGAGTCTTTGAACGCAAGTTGCGCCCGAAGCCGTT
AGGCCGAGGGCACGTCTGCATGGGCGTCACGCATCGCGTCGCCTCCCTTAACTTAATTGTTTACAA
AACAAGTCAAGGAAAGGGGGAGCGGATACTGGCCTCCCGTGCCTTGCGGCGCGGCTGGCTCAAAACGGAGTCC
CCCGCGAAGGACGCACGACAAGTGGTGGTTGATAACAAGGCCCTCGCGTCCCGTCGTGCGCACGTCCTGCGATGGGTTG
GCTCTCGTGACCCTGACGCGTCTAGGCTTAAGCCTAAGGCGCTCCGACCGCGACCCCATGTCAGGCGGACYWACCCCSSSSKG
Poria cocos (Schw.)
Wolf.
GCGAAATGSGATACTTGGTGTGAATTGCAGAATCCCGTGAACCATCGAGTCTTTGAACGCAAGTTGCGCCCGAAGCCATT
AGGTTGAGGGCACGTCTGCCTGGGCGTCACATATCGTTGCCCGATGCCTATTGCAGTGTGATAGGA
ATTTTTAGGGCGAATGATGGCTTCCCGTGAGCGTTGTTGCCTYGCGGYTGGTTGAAAATTGAGTCCTTGGTGGG
GTGTGCCATGATAGATGGKGGTCGAGTTAGCACGAGACCCATCATGTGTACGCTCCCCAWAATAKGGCTTYGATGACCC
ACATGCGTCTTTTGACTCTCATGACGAGACCTCAGGTCAGGCGGACACCCSSGATC
Atractylodes
macrocephalan Koidz.
GCAAAATGCGATACTTGGTGTGAATTGCAGAATCCCGTGAACCATCGAGTTTTTGAACGCAAGTTGCGCCCGAAGCCATT
CGGCCGAGGGCACGTCTGCCTGGGCGTCACGCATCGCGTCGCCCCCGACCACGCCTCCCCCACGGGG
ACGCGTGTCGTCGGGGGCGGAGATTGGTCTCCCGTGCCCACGGCGCGGCTGGCCTAAACGGGAGTCCCCTTCGA
CGGACGCACGGCTAGTGGTGGTTGTAATGGCCCTCGTATTGAGCCGTGCGTCGCGAGCCGCAAGGGAAGCGCTCGACAA
AGACCCCAACGCGTCGCCTTGCGACGACGCTTCGACCGCGACCCCAGGTCAGGCGGACTGCCTCC
Glycyrrhiza uralensis
Fisch.
GCGAAATGCGATACTTGGTGTGAATTGCAGAATCCCGTGAACCATCGAGTCTTTGAACGCAAGTTGCGCCCGAAGCCATT
AGGCCAAGGGCACGTCTGCCTGGGTGTCACAGACCGTTGCCCGATGCCAATTGCCTCGCGATAGGTA
CTTTGGTTGTGCAGGGTGAATGTTGGCTTCCCGTGAGCATTGCGGCCTCACGGTTGGCTCAAAACTGAGTCCAT
GGTAGGGTTTGGCATGATCGATGGTGGTTGAGTGACGCTCGAGACCAATCATGTGTGACTCCACTGAGTTTGGGCTCTGTA
ACCAATAGGCGTCTTTGAACGCTCGTGATGAGACCTCAGGTCAGGCGGGCACCCSGCSTTG
Astragalus
membranaceus
(Fisch.) Bunge.
GCGAAATGCGATACTTGGTGTGAATTGCAGAATCCCGTGAACCATCGAGTCTTTGAACGCAAGTTGCGCCCGAAGCCATT
AGGTTGAGGGCACGTCTGCCTGGGCGTCACATATCGTTGCCCGATGCCTATTGCAGTGTGATAGGAAT
TTTTAGGGCGAATGATGGCTTCCCGTGAGCGTTGTTGCCTCGCGGCTGGTTGAAAATTGAGTCCTTGGTGGGGT
GTGCCATGATAGATGGTGGTCGAGTTAGCACGAGACCCATCATGTGTACGCTCCCCATAATATGGCTTCGATGACCCACA
TGCGTCTTTTGACTCTCATGACGAGACCTCAGGTCAGGCGTCAGCATC
Ligustrum lucidum Ait. GCAAAATGCGATACTTGGTGTGAATTGCAGAATCCCGTGAACCATCGAGTTTTTGAACGCAAGTTGCGCCCGAAGCCATT
ATGCCGAGGGCACGTCTGCCTGGGCGTCACGCATAGCGTCGCCCTCCACCTCCGTCCTTAAACGGGTCG
TAGGTGTTTGGGTTGGATATTGGCATCCCGTGCATCTCGGTGTGCGGTTGGCCTAAATGTGATTCGGCATCGAC
GTATGTCTCGACAATTGGTGGTTGAAGACCTCAACTTTCGTTTTGTCGTGCTAGATTACGTTGCTTGGCTCGAATGCG
TTGACCCCGACGGTGCTTTGCACTTCGACAGAGACCCCAGGTCAGGCGGATGCCCGA
Agastache rugosa
(Fisch.et Mey.) O. Ktze.
GCGAAATGCGATACTTGGTGTGAATTGCAGAATCCCGTGAACCATCGAGTCTTTGAACGCAAGTTGCGCCCGAAGCCATT
AGGCCGAGGGCACGTCTGCCTGGGCGTCACGCATCGCGTGCCCCCTGACGCAGCGCGGCCGAGGTGGGG
CGGCC
CATG
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qCGGATATTCGCCCCGTGGCCCGGCACGCGGT
GGTTGAACTCATCAATCTCGCGCCGTCGTGCT
TGCCTCACGGCTCACCACCTTCGAC
.4. Measurements
The biochemistry measurements including glutamate oxaloac-
tate transaminase (GOT), glutamate pyruvate transaminase
GPT), alpha-fetoprotein (AFP), alkaline phosphatase, -glutamyl
ranspeptidase, albumin, total bilirubin, blood urea nitrogen, serum
reatinine, total cholesterol, triglyceride, fasting blood sugar,
Abbott Laboratories, North Chicago, IL), and virologic response
ncluding HCV-RNA levels and HCV genotypes (Roche Diagnos-
ics) were assessed at the clinical pathology laboratory of the
uthors’ afﬁliated hospital using routine automated techniques. All
easurements were taken at 0800–0900, following an overnight
ast, using standardised methods. The whole-blood sample was
rawn and centrifuged at 4 ◦C. A 1 mL  aliquot of the sample was
apidly frozen at −80 ◦C for the HCV RNA level analysis with the
OBAS® TaqMan® HCV Real-time PCR (Roche Diagnostics, USA).
 self-administered questionnaire was used to evaluate subjec-
ive symptoms, compliance and health-related quality of life (QOL).
ll measurements were taken at the beginning and the end of the
tudy.
.5. Quality-of-life questionnaire
To assess the QOL of our subjects, we used the Taiwanese version
f the self-administered quality-of-life questionnaire WHOQOL-
REF, which is well validated with consistency coefﬁcients ranging
rom 0.70 to 0.77.21 The WHOQOL-BREF questionnaire evaluates
uality of life in the physical, psychological, social, and environ-CAAATGCGATCCCTCCGACTCGGTGTCGCGACAAGTGGT
CGTCGTCCGATCGGGCATCATTGAACGACCCAACGGTGTCGG
mental domains, with scores ranging from 0 to 100. Higher scores
represent better health.
2.6. Statistical analysis
The data were analysed using SPSS software (version 17.0,
Chicago, IL.). Student’s t-test was used to compare the mean
between the KSY and control groups. A paired t-test was  used to
compare within-group means at 0 and 6 weeks. All p values were
two-tailed, and an  level of 0.05 was considered statistically sig-
niﬁcant. Our previous trial reported mean GPT levels of 77.5 IU/L at
baseline, with a reduction to 56.2 IU/L at follow-up. Furthermore,
the standard deviation (SD) in GPT levels was 33.7 IU/L in a previ-
ous series of 60 patients with chronic hepatitis B.18 Thus, based on
our own experience, it was  calculated that to detect a reduction in
GPT level of 21.2 IU/L with a signiﬁcance level of 0.05 and a power
of 0.8, 63 patients would be required. Allowing for a 10% dropout
rate, 70 patients would be needed for this study.
3. Results
3.1. Comparison among groups at baseline
Data were analysed on a per-protocol basis, with subject exclu-
sion occurring before the release of the blinding procedure. A total
of 85 subjects were enrolled. Twelve subjects did not receive their
allocated intervention because they met  the exclusion criteria.
Three subjects were excluded because they failed to attend study
visits due to work commitments or moving out of the area. In the
118 C.-Y. Liu et al. / Complementary Therapies in Medicine 27 (2016) 114–122
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(Fig. 2. HPLC analysis of extract
nd, 70 subjects were randomly assigned. An additional 6 subjects
n the KSY group and 7 subjects in the placebo group discontin-
ed the intervention. Consequently, the data reported are from 57
ubjects (Fig. 1).
Baseline characteristics for both placebo and KSY groups are
hown in Table 3. No signiﬁcant differences between any of the
roup means were detected in demographic, disease duration,
enal, and liver function parameters.
.2. Comparison within groups after the 6-week intervention
The 6-week treatment with the herbal decoction KSY resulted
n a decrease in GOT from 83.2 ± 53.0 IU/L to 62.9 ± 29.0 IU/L
p = 0.024) and a decrease in GPT from 106.3 ± 78.2 IU/L to
4.7 ± 32.2 IU/L (p = 0.031) compared with baseline measurements,
s shown in Table 4. The liver enzyme Alk-p decreased from
05.6 ± 41.0 to 92.3 ± 34.4 in the KSY group. Despite the 13.2 ± 36.4
ecrease in Alk-p in the KSY group, compared with a 4.8 ± 38.7
ecrease in the placebo group, the difference was not statistically
igniﬁcant; thus, KSY caused only a decreasing trend in serum
lkaline phosphatase (p = 0.061). A decreasing trend in gamma  GT
n the KSY group was also noted (p = 0.090). KSY led to signif-
cant decrease in serum triglyceride, from 115.3 ± 50.8 mg/dL to
8.5 ± 41.7 mg/dL (p = 0.003), and a signiﬁcant increase in serum
lbumin (3.9 ± 0.3 g/dL to 4.0 ± 0.3 g/dL; p = 0.015). The changes in
ther parameters, including bilirubin, AFP, anthropometric data,
aematopoietic function, and life quality, did not reach signiﬁcance
fter the 6-week course.
No statistically signiﬁcant differences were detected for any
ther variables assessed after 6 weeks in the placebo group
Table 4). KSY and its constituted herbs.
3.3. Comparison between groups after the 6-week intervention
Table 5 summarises the changes in all measurements taken
before and after 6 weeks of intervention. Changes were calculated
using the following formula: (baseline values – post-treatment val-
ues). A negative change indicates an increase or elevation of the
parameter.
Regarding liver function proﬁles, GOT decreased signiﬁcantly
(20.3 ± 45.7 IU/L) in the KSY group and increased (2.3 ± 37.9 IU/L)
in the control group (p = 0.047) after 6 weeks of intervention. GPT
also decreased signiﬁcantly (31.7 ± 75.2 IU/L) in the KSY group and
increased (−6.9 ± 50.6 IU/L) in the control group (p = 0.027) after 6
weeks of intervention (Fig. 3).
Regarding HCV viral load, HCV RNA decreased from 5.1 ± 2.4
log IU/mL to 4.7 ± 2.5 log IU/mL in the KSY group and increased
slightly from 5.1 ± 2.2 log IU/mL to 5.3 ± 2.1 log IU/mL in the
placebo group. Neither group showed a statistically signiﬁ-
cant change in the within-group analysis. Notably, HCV RNA
decreased by 0.3 ± 1.2 log IU/mL in the KSY group and increased
by 0.1 ± 0.5 log IU/mL in the placebo group (Fig. 3c), a sta-
tistically signiﬁcant difference in the between-group analysis
(p = 0.047). Among the lipid proﬁles, serum triglyceride decreased
by 16.9 ± 27.5 mg/dL in the KSY group and increased by
4.2 ± 40.2 mg/dL in the placebo group, a statistically signiﬁcant dif-
ference existed in the between-group analysis (p = 0.026).
3.4. Compliance
To monitor compliance, the subjects were required to return
all packaging and any unused packages. Each subject received 42
packages, and on average, 1.1 ± 1.2 unused packages per subject
(1.1 ± 1.2 packages from the KSY group and 1.2 ± 1.7 packages from
the placebo group) were returned, indicating that more than 97%
of the doses were taken (Table 3).
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Table  3
Demographic data, viral load, and serum liver function of the participants at baseline.
Demographics KSY (n = 29) Control (n = 28) P-value
Age (years) 57.0 ± 7.0 60.3 ± 7.5 0.090
Gender  (male: female) 12:17 13:15 0.701
Disease  duration (years) 14.4 ± 10.2 14.5 ± 8.2 0.949
HCV  genotype 1 22 20 0.926
HCV  genotype 2 6 7
HCV  genotype 3 1 1
Body  weight (kg) 58.1 ± 8.4 58.8 ± 7.8 0.205
Systemic blood pressure (mmHg) 131.7 ± 22.4 124.7 ± 10.5 0.220
Diastolic blood pressure (mmHg) 80.1 ± 16.8 75.3 ± 12.9 0.362
Heart  rate (bpm) 79.8 ± 12.7 76.6 ± 7.8 0.387
GOT  (IU/L) 83.2 ± 53.0 68.1 ± 37.6 0.220
GPT  (IU/L) 106.3 ± 78.2 84.3 ± 45.9 0.198
HCV  RNA (log IU/mL) 5.1 ± 2.4 5.1 ± 2.2 0.937
-fetoprotein (ng/mL) 9.7 ± 14.3 17.7 ± 30.7 0.219
Albumin (g/dL) 3.9 ± 0.3 3.9 ± 0.4 0.621
Total  bilirubin (mg/dL) 0.93 ± 0.45 0.80 ± 0.27 0.211
Alkaline  phosphatase (U/L) 105.6 ± 41.0 110.9 ± 57.2 0.686
-glutamyl transpeptidase (U/L) 102.3 ± 171.6 81.6 ± 117.4 0.597
Blood  urea nitrogen (mg/dL) 13.2 ± 2.8 15.4 ± 5.5 0.063
Creatinine (mg/dL) 0.69 ± 0.19 0.80 ± 0.22 0.057
Platelet  (103/uL) 152.9 ± 67.5 146.5 ± 63.8 0.712
Unused  packages 1.07 ± 1.22 1.21 ± 1.66 0.660
Abbreviation: Hepatitis C virus (HCV), Glutamate oxaloacetate transaminase (GOT), Glutamate pyruvate transaminase (GPT)
Table  4
Within-group analysis at baseline and after 6 weeks of study patients.
Outcomes KSY group (n = 29) Control group (n = 28)
Baseline 6 weeks P value Baseline 6 weeks P value
Body weight (kg) 55.5 ± 6.6 55.3 ± 6.2 0.516 59.1 ± 7.4 58.8 ± 7.3 0.263
Systemic blood pressure (mmHg) 130.6 ± 28.3 131.0 ± 17.8 0.938 129.8 ± 7.9 127.6 ± 12.3 0.546
Diastolic blood pressure (mmHg) 78.3 ± 24.1 77.1 ± 15.0 0.885 75.4 ± 9.7 72.9 ± 7.5 0.316
Heart  rate (bpm) 77.8 ± 14.7 79.3 ± 13.5 0.709 73.9 ± 8.3 74.7 ± 13.9 0.791
Blood  urea nitrogen (mg/dL) 13.2 ± 2.8 14.0 ± 4.4 0.171 15.4 ± 5.5 16.5 ± 6.2 0.185
Creatinine (mg/dL) 0.7 ± 0.2 0.6 ± 0.2 0.028* 0.8 ± 0.2 0.8 ± 0.3 0.791
Platelet (103/uL) 152.9 ± 67.5 150.4 ± 64.9 0.429 146.5 ± 63.8 142.6 ± 54.9 0.280
Hemoglobin (g/dL) 13.6 ± 2.5 14.0 ± 1.5 0.277 13.4 ± 1.8 13.6 ± 1.5 0.384
Leukocyte count (103/uL) 4.7 ± 1.5 4.6 ± 1.7 0.485 4.9 ± 2.6 4.8 ± 1.7 0.651
WHOQOL BREF
Physical scores 66.9 ± 11.3 68.7 ± 10.3 0.344 62.1 ± 12.3 64.8 ± 10.3 0.295
Mental scores 72.3 ± 13.2 73.9 ± 10.9 0.439 71.0 ± 12.3 70.2 ± 13.0 0.731
Social scores 74.4 ± 11.4 75.6 ± 11.0 0.457 71.5 ± 15.3 70.8 ± 12.1 0.739
Environmental scores 78.3 ± 12.0 78.3 ± 10.7 1.000 73.7 ± 14.3 73.9 ± 11.0 0.939
HCV  RNA (log IU/mL) 5.1 ± 2.4 4.7 ± 2.5 0.120 5.1 ± 2.2 5.3 ± 2.1 0.163
GOT  (IU/L) 83.2 ± 53.0 62.9 ± 29.0 0.024* 68.1 ± 37.6 70.4 ± 49.8 0.749
GPT  (IU/L) 106.3 ± 78.2 74.7 ± 32.2 0.031* 84.3 ± 45.9 91.2 ± 61.4 0.473
Alkaline phosphatase (U/L) 105.6 ± 41.0 92.3 ± 34.4 0.061 110.9 ± 57.2 106.1 ± 49.4 0.516
-glutamyl transpeptidase (U/L) 102.3 ± 171.6 81.1 ± 113.2 0.090 81.6 ± 117.4 75.2 ± 95.5 0.308
Albumin (g/dL) 3.9 ± 0.3 4.0 ± 0.3 0.015* 3.9 ± 0.4 4.0 ± 0.4 0.324
Total  Bilirubin (mg/dL) 0.9 ± 0.5 0.9 ± 0.4 0.673 0.8 ± 0.3 0.8 ± 0.3 0.539
-fetoprotein (ng/mL) 9.7 ± 14.3 10.9 ± 20.4 0.359 17.7 ± 30.7 18.5 ± 31.5 0.402
Fasting glucose (mg/dL) 109.4 ± 41.2 111.4 ± 37.6 0.669 107.1 ± 67.1 106.6 ± 24.4 0.965
Triglyceride (mg/dL) 115.3 ± 50.8 98.5 ± 41.7 0.003* 104.6 ± 45.4 108.8 ± 52.7 0.587
Total  cholesterol (mg/dL) 176.8 ± 37.9 174.2 ± 32.9 0.372 165.0 ± 32.6 171.5 ± 47.2 0.170
Note: data expressed as mean ± standard deviation. Abbreviation: hepatitis C virus (HCV), Glutamate oxaloacetate transaminase (GOT), Glutamate pyruvate transaminase
(
T
3
g
a
r
s
w
o
wGPT).
he  bold values indicate the difference with statistical signiﬁcance.
* p < 0.05.
.5. Adverse effects
One subject in the KSY group experienced symptoms of epi-
astric dullness, and one subject in the placebo group experienced
bdominal discomfort. In both patients, these symptoms were
esolved within 3 days after treatment. Both they continued in the
tudy. No major adverse events of either KSY or placebo group
ere noted. In addition, no subjects experienced renal impairment
r bone marrow function suppression in this study. No subjects
ithdrew from the study because of discomfort or adverse effects.4. Discussion
This study used the herbal decoction KSY to treat patients with
chronic hepatitis C whose GPT levels were between 40 and 200 IU/L.
KSY not only lowered serum GOT by 24.4% and GPT by 29.7% but
also lowered the HCV RNA viral load by 0.3 log IU/mL. This ﬁnding
implied KSY is the ﬁrst TCM formula with both improving liver
function and antiviral activity in CHC. This signiﬁcant result might
be related to the immunomodulatory and anti-cancer effects in vivo
and in vitro in individual puriﬁed compounds and herbal extracts
of KSY.22–31
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Table 5
Between-group analysis of viral load and liver enzymes of study patients.
Outcomes KSY (n = 29) Control (n = 28) P-value
GOT (IU/L) 20.3 ± 45.7 −2.3 ± 37.9 0.047*
GPT (IU/L) 31.7 ± 75.2 −6.9 ± 50.6 0.027*
Alkaline phosphatase (U/L) 13.2 ± 36.4 4.8 ± 38.7 0.404
-glutamyl transpeptidase (U/L) 21.2 ± 65.0 6.4 ± 32.8 0.282
Albumin (g/dL) −0.09 ± 0.19 −0.06 ± 0.30 0.596
Total bilirubin (mg/dL) −0.01 ± 0.20 −0.03 ± 0.27 0.802
-fetoprotein (ng/mL) −1.2 ± 6.8 −0.8 ± 5.0 0.815
HCV  RNA (log IU/mL) 0.3 ± 1.2 −0.1 ± 0.5 0.047*
Platelet (103/uL) 2.5 ± 18.5 3.9 ± 18.7 0.781
Hemoglobin (g/dL) −0.4 ± 1.8 −0.2 ± 1.0 0.576
Leukocyte count (103/uL) 0.11 ± 0.85 0.14 ± 1.64 0.931
Fasting glucose (mg/dL) −2.0 ± 25.3 0.4 ± 51.8 0.822
Blood urea nitrogen (mg/dL) −0.8 ± 2.9 −1.1 ± 4.1 0.754
Creatinine (mg/dL) 0.05 ± 0.11 0.01 ± 0.14 0.230
Triglyceride (mg/dL) 16.9 ± 27.5 −4.2 ± 40.2 0.026*
Total cholesterol (mg/dL) 2.5 ± 14.9 −6.5 ± 24.4 0.100
WHOQOLBREF
Physical scores 4.7 ± 21.2 2.5 ± 22.8 0.713
Mental scores 5.5 ± 23.2 6.3 ± 22.9 0.905
Social scores 5.2 ± 20.5 6.4 ± 23.6 0.831
Environmental scores 6.9 ± 22.7 5.9 ± 25.6 0.876
Note: difference was  calculated by pretest value minus posttest value. Data expressed as mean ± standard deviation. Abbreviation: hepatitis C virus (HCV), Glutamate
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The anti-inﬂammatory effect of KSY may  be due to the
mmunoregulatory properties of its ingredients. Codonopsis pilo-
ula polysaccharide attenuated sepsis by circulating regulatory
 cells and CD4 T cell activation in a mouse model.31 Astra-
alus membranaceus polysaccharides enhanced immune responses
o the HBV DNA vaccine by promoting dendritic cell matura-
ion and inhibiting the regulatory T cell frequency in mice.25
tractylodes macrocephala polysaccharide exerted hepatoprotec-
ive effects in a rat model of hepatic ischaemia-reperfusion injury
ia antioxidant, free radical-scavenging activity and the inhibi-
ion of NF-kB.32 Acacetin, a ﬂavonoid isolated from Agastache
ugosa, protects against d-galactosamine and lipopolysaccharide-
nduced liver injury by suppressing TLR4 signalling and enhancing
utophagic ﬂux.28 Another study that evaluated the hepatoprotec-
ive effect of an herbal formula, Xiao Chai Hu Tang (XCHT) 33, on
3 chronic hepatitis C patients observed improvements in GOT (16
ubjects) and GPT (18 subjects), and 9 subjects showed improve-
ents in the histology activity index score. In addition, this formula
ad tumour suppressing effects.34 However, case reports of acute
rug-induced liver injury highlighted the safety concerns associ-
ted with using XCHT 35. Other hepatoprotective herbs including,
raptopetalum paraguayense,  an herbal food in Taiwan, signiﬁcantly
educed toxin-induced hepatic inﬂammation and ﬁbrosis in rats,36,
7 and the herbal formula San-Huang-Xie-Xin-Tang suppressed
CV replication and virus-induced cyclooxygenase-2 expression in
n in vitro study.38 Because clinical trials of these herbs have not
een conducted yet, their effects in humans are still unknown.
The decrease of HCV RNA viral load in subjects receiving KSY
uggests that KSY exhibits anti-HCV virus activity. To our knowl-
dge, KSY is the ﬁrst clinically used herbal formula to exhibit
nti-HCV activity. Antiviral activity has been demonstrated for
ome of the ingredients in KSY, including Glycyrrhiza uralensis
isch. and Ligustrum lucidum Ait.39–41 Glycyrrhizin has been shown
o inhibit the release of infectious HCV particles, and several
ompounds obtained from Glycyrrhiza uralensis Fisch. also exhibit
nti-HCV activity.39 Oleanolic acid and ursolic acid, two aqueous
xtracts from Ligustrum lucidum Ait., directly inhibit the activity
f HCV NS5B RNA-dependent RNA polymerase and inhibit the
eplication of the HCV genotype 1b and HCV genotype 2a JFH1
irus.41 Thus, the antiviral effects of KSY may  be due to its activityagainst multiple targets, warranting further studies to investigate
the underlying mechanism.
The HCV genotype in this study ranged from 1 to 3. There was
no difference in genotype distribution between the study groups.
Subgroup analysis showed that KSY signiﬁcantly improved liver
function in the genotype 1 subgroup and signiﬁcantly lowered HCV
viral load in the genotype 2 subgroup (data not shown). This dif-
ference suggests that the therapeutic effect of KSY is inﬂuenced by
the HCV genotype, similar to other antiviral natural agents.7
Previous studies reported chronic infection with HCV decreases
health-related QOL.42 Interferon based therapy and its treatment
duration adversely affects QOL of patients with HC.43 In spite of
improved liver function and viral load, our study showed that QOL
didn’t change signiﬁcantly in both KSY and placebo groups. It may
be related to too short treatment duration to fully evaluate its
efﬁcacy. Further study with longer follow-up time would be war-
ranted.
Interestingly, KSY lowered the serum triglyceride level and
HCV RNA viral load in patients with CHC, which implies KSY may
regulate the triglyceride metabolism and further inﬂuence the
triglyceride-rich lipoprotein formed HCV lipo-viro-particle fusion
to host membrane. Patients with CHC had higher steatosis, higher
triglyceride levels and lower total density lipoprotein cholesterol
levels.44 Agents affecting the lipids and receptors for lipids may  play
a role in the early stages of HCV infection, such as epigallocatechin-
3-gallate, a compound of green tea extract, decreasing cell secretion
of apolipoprotein-B100 to prevent virion attachment to hepato-
cytes. Ezetimibe, a lipid lowering agent, would block HCV entry
immediately before or at the fusion stage.45 The molecules inhibit-
ing HCV entry and/or fusion would likely act on extracellular
targets, thereby protecting hepatocytes and limiting virus-induced
cell damages.46
To prevent further virus-facilitated tumorigenesis, many stud-
ies have focused on the antitumor effects of herbal medicines
for CHC.16, 47 Among these medicines, XCHT and some of its
components have been shown to directly target tumour growth,
metastasis, and invasion.34 Interestingly, KSY also demonstrated
a direct tumour-suppressing effect in both in vivo and in vitro
studies.48 Thus, further investigations on a larger scale and for a
C.-Y. Liu et al. / Complementary Therapie
Fig. 3. The distribution plot of reduction of GPT, GOT, and HCV RNA viral load after
6  weeks. The horizontal line indicates the mean value of each group; the error bar
indicates the 95% conﬁdence interval for mean of each group. (a) tahe reduction of
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multicenter community-based study. Kaohsiung J Med  Sci.  2010;26:461–469.PT after 6 weeks. (b) tbhe reduction of GOT after 6 weeks. (c) tche reduction of
CV RNA viral load after 6 weeks.
onger period are warranted to evaluate the antiviral and antitumor
ffects of KSY and its component ingredients.
Comparing to latest antiviral agents including Sofosbuvir and
elpatasvir,49 KSY is not effective enough to achieve sustained
irologic response. However, the efﬁciency on hepatoprotection of
SY for CHC patient unsuccessfully treated with interferon-based
herapy may  be worthy being evaluated rather than silymarin.50esides, the effect on triglycerides of KSY is better than silymarin,51
nd this may  imply the therapeutic potential of KSY in treating
on-alcoholic fatty liver disease.s in Medicine 27 (2016) 114–122 121
There are some limitations in this study. When compared with
the duration of standard treatment (at least 24 weeks), 6 weeks of
treatment with KSY may  be too short to fully evaluate its efﬁcacy.
Although this study showed the hepatoprotective effects and rela-
tive safety of KSY, the long-term effects of KSY are still unknown. In
addition, participant’s diet and lifestyle could not be restricted, and
this may  have also contributed to the ﬁndings. Although this study
demonstrate the association of KSY on lipid metabolism and viral
clearance, the underlying mechanism is unclear and worth further
investigation.
5. Conclusion
The present study showed a signiﬁcant improvement in the lev-
els of GOT and GPT and a trend towards decreased HCV viral load in
patients with CHC after treatment with KSY for 6 weeks. Daily use of
KSY for 6 weeks is safe and free of severe adverse effects for patients
with CHC. The long-term effects of KSY on lipid metabolism asso-
ciated hepatoprotection and viral clearance should be investigated
in the future.
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